Biolife Solutions
BLFS on Nasdaq. Biolife Solutions sells biopreservation media and cell processing tools to cell and gene therapy developers. Market value $1.9bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $0.43 of spare cash in the past 12 months. A savings account pays about $4.
You pay 1067.1 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns -4 cents a year. Above 10 is good.
Quality score: 48 of 100. Price score: 19 of 100. Our list needs 70 on quality and 60 on price.
$38.61 a share, 116% above its 1-year low
Over the past year the price has ranged from $17.86 to $39.76.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $119m | $76m | $68m | $75m | $96m |
| Operating margin | |||||
| Operating margin | -29.5% | -7.8% | -25.3% | -6.0% | -17.3% |
| Debt to equity | |||||
| Debt to equity | 0.02 | 0.07 | 0.08 | 0.05 | 0.01 |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.05bn | 0.05bn | 0.05bn |
Health checks
- Free cash flow positive2 of 5 years
- Accounting looks honest (Beneish)Nothing unusual
- Financial strength (Piotroski)5 of 9
- Profit backed by cash (accruals)Yes
- Debt0.01× equity
- Revenue growth, five yearsStrong, 14.9% a year
- Buying back its own sharesNo, 14% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $28 million last quarter, up 21% on a year ago.
- Profit: $45 million, after a loss of $16 million a year ago.
- It keeps 2 cents of each $1 of sales as operating profit, after losing 20 cents a year earlier.
- 3% more shares than a year ago. Each share owns a bit less of the company.
- It has $24 million more cash than debt, up from $22 million a year ago.
| Quarter to | Amount |
|---|---|
| September 2024 | $21m |
| December 2024 | Not reported |
| March 2025 | $22m |
| June 2025 | $23m |
| September 2025 | $28m |
| December 2025 | $19m |
| March 2026 | $28m |
| June 2026 | $28m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$2m |
| December 2024 | Not reported |
| March 2025 | -$448,000 |
| June 2025 | -$16m |
| September 2025 | $621,000 |
| December 2025 | $11m |
| March 2026 | $1m |
| June 2026 | $45m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 February 2026
- Next quarterly (estimated, 10-Q)
- 5 November 2026
Who owns it
2 long-term investors we follow own it, up from 1 last quarter. 216 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Royce & AssociatesChuck Royce | $18m | 0.1% | Added |
| Diamond Hill Capital ManagementRic Dillon (founder) | $4m | <0.1% | New |
Largest holders overall
- T. Rowe Price Investment Management$191mAdded
- BlackRock$180mAdded
- Casdin Capital$131mCut
- Invesco$63mCut
- Vanguard Capital Management$55mAdded
- State Street$47mAdded
- Geode Capital Management$31mAdded
- Massachusetts Financial Services$30mCut
- Fred Alger Management$30m
- Dimensional Fund Advisors LP$30m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
4 investors own more than 5%.
- Casdin Capital, LLCPassive investorat least 9.7%0.0 pts(filed with 3 related holders)Since 4 June 2026
- Casdin Partners Master Fund, L.P.Passive investorat least 9.7%−2.7 pts(filed with 2 related holders)Since 20 May 2026
What they said
The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate…
Read the filing - T. Rowe Price Investment Management, Inc.Passive investor7.5%−6.0 ptsSince 31 August 2026
- Glazer Capital, LLCPassive investorat least 5.5%(filed with 1 related holder)Since 17 September 2026
- Invesco Ltd.Passive investorSold down below 5%Since 31 March 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Casdin Capital, LLC Passive investor | at least 9.7%0.0 pts (filed with 3 related holders) | 4 June 2026 | |
Casdin Partners Master Fund, L.P. Passive investor | at least 9.7%−2.7 pts (filed with 2 related holders) | 20 May 2026 | What they saidThe Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate… Read the filing |
T. Rowe Price Investment Management, Inc. Passive investor | 7.5%−6.0 pts | 31 August 2026 | |
Glazer Capital, LLC Passive investor | at least 5.5% (filed with 1 related holder) | 17 September 2026 | |
Invesco Ltd. Passive investor | Sold down below 5% | 31 March 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 9 sold $7m, $1m of it under preset trading plans.
- Foster Karen A.Chief Quality and OperationsSoldunder a preset trading plan
- Date
- 23 March 2026
- Shares
- 2,577
- Price
- $19.17
- Value
- $49,401
- Foster Karen A.Chief Quality and OperationsSold
- Date
- 9 March 2026
- Shares
- 500
- Price
- $20.00
- Value
- $10,000
- Foster Karen A.Chief Quality and OperationsSold
- Date
- 5 March 2026
- Shares
- 96,923
- Price
- $20.15
- Value
- $2m
- Werner SeanChief Technology OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 111
- Price
- $20.74
- Value
- $2,302
- Foster Karen A.Chief Quality and OperationsSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 418
- Price
- $20.74
- Value
- $8,669
- Mathew Aby J.EVP & Chief Scientific OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 529
- Price
- $20.74
- Value
- $10,971
- Wichterman TroyChief Financial OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 588
- Price
- $20.74
- Value
- $12,195
- Aebersold SarahChief Human Resources OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 219
- Price
- $20.74
- Value
- $4,542
- Berard ToddChief Marketing OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 353
- Price
- $20.74
- Value
- $7,321
- Wichterman TroyChief Financial OfficerSoldunder a preset trading plan
- Date
- 6 January 2026
- Shares
- 990
- Price
- $25.59
- Value
- $25,334
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 23 March 2026 | Foster Karen A. Chief Quality and Operations | Sold under a preset trading plan | 2,577 | $19.17 | $49,401 |
| 9 March 2026 | Foster Karen A. Chief Quality and Operations | Sold | 500 | $20.00 | $10,000 |
| 5 March 2026 | Foster Karen A. Chief Quality and Operations | Sold | 96,923 | $20.15 | $2m |
| 3 March 2026 | Werner Sean Chief Technology Officer | Sold under a preset trading plan | 111 | $20.74 | $2,302 |
| 3 March 2026 | Foster Karen A. Chief Quality and Operations | Sold under a preset trading plan | 418 | $20.74 | $8,669 |
| 3 March 2026 | Mathew Aby J. EVP & Chief Scientific Officer | Sold under a preset trading plan | 529 | $20.74 | $10,971 |
| 3 March 2026 | Wichterman Troy Chief Financial Officer | Sold under a preset trading plan | 588 | $20.74 | $12,195 |
| 3 March 2026 | Aebersold Sarah Chief Human Resources Officer | Sold under a preset trading plan | 219 | $20.74 | $4,542 |
| 3 March 2026 | Berard Todd Chief Marketing Officer | Sold under a preset trading plan | 353 | $20.74 | $7,321 |
| 6 January 2026 | Wichterman Troy Chief Financial Officer | Sold under a preset trading plan | 990 | $25.59 | $25,334 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 7 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It isn't cheap on profits: 1067.1× operating profit.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.